ERIKA MEJIA: Open Payments
NPI 1942654025 · BRONX, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,913 in 67 payments from 15 companies in 2025. Trend: 2023 $692 · 2024 $900 · 2025 $1,913
Food & beverage: $1,913
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 16 | $585 |
| ABBVIE INC. | 14 | $352 |
| Novo Nordisk Inc | 10 | $237 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $169 |
| Lilly USA, LLC | 7 | $144 |
| Teva Pharmaceuticals USA, Inc. | 2 | $130 |
| Astellas Pharma US Inc | 3 | $55 |
| Corcept Therapeutics | 2 | $41 |
| Dexcom, Inc. | 1 | $38 |
| Phathom Pharmaceuticals, Inc. | 1 | $35 |
Products named: FANAPT, VRAYLAR, HETLIOZ, CAPLYTA, UZEDY, Ozempic, Rybelsus, MOUNJARO.
Industry payments across NY — which companies pay providers there.
